UB Paderborn / Katalog / Suche / in CDI

Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management

Haematologica (Roma), 2014-11, Vol.99 (11), p.1671

2014

Link zum Volltext

Verfügbarkeit prüfen

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2023-06, Vol.388 (26), p.2444-2455

2023

Link zum Volltext

Verfügbarkeit prüfen

Mit welcher CED-Therapie in die Schwangerschaft?

Gastro-News, 2018-02, Vol.5 (1), p.6-7

Howaldt, Stefanie

2018

Link zum Volltext

Verfügbarkeit prüfen

Tu1717 - Cedur: Implementation of a Long-Term Observation Registry in German IBD Patients

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-998-S-998

2018

Link zum Volltext

Verfügbarkeit prüfen

Iron Replacement Therapy for Secondary Thrombocytosis in Inflammatory Bowel Disease: Results of a Randomized Controlled Study – The ThromboVIT Trial

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (5), p.S-265-S-266

2011

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to: Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial

Inflammatory bowel diseases, 2022-03, Vol.28 (3), p.494-494

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial

Inflammatory bowel diseases, 2022-03, Vol.28 (3), p.373-384

2022

Link zum Volltext

Verfügbarkeit prüfen

Su2091 Results of a Phase II, Randomized, Double Blind, Controlled Trial of the Efficacy of Active Therapeutic Immunization With TNF-Kinoid in Patients With Moderate to Severe Crohn's Disease With Secondary Resistance to TNFα Antagonist

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-567-S-568

2012

Link zum Volltext

Verfügbarkeit prüfen

Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program

Inflammatory bowel diseases, 2015-03, Vol.21 (3), p.579-588

2015

Link zum Volltext

Verfügbarkeit prüfen

Recombinant Erythropoietin for the Treatment of Anemia in Inflammatory Bowel Disease

The New England journal of medicine, 1996-03, Vol.334 (10), p.619-624

1996

Link zum Volltext

Verfügbarkeit prüfen

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a Phase 3 study

Alimentary pharmacology & therapeutics, 2016-08, Vol.44 (3), p.259-270

2016

Link zum Volltext

Verfügbarkeit prüfen

867e: EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-1393-S-1394

2022

Link zum Volltext

Verfügbarkeit prüfen

Letter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area

Alimentary pharmacology & therapeutics, 2020-09, Vol.52 (5), p.898-899

2020

Link zum Volltext

Verfügbarkeit prüfen

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease

Journal of Crohn's and colitis, 2017-04, Vol.11 (4), p.390-399

2017

Link zum Volltext

Verfügbarkeit prüfen

Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial

Inflammatory bowel diseases, 2013-07, Vol.19 (8), p.1609-1616

2013

Link zum Volltext

Verfügbarkeit prüfen

Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study

Journal of Crohn's and colitis, 2014-11, Vol.8 (11), p.1471-1479

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency

European journal of drug metabolism and pharmacokinetics, 2017-04, Vol.42 (2), p.229-238

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease

Zeitschrift fur Gastroenterologie, 2021-11, Vol.59 (11), p.1189

2021

Link zum Volltext

Verfügbarkeit prüfen

Compassionate Use of Certolizumab Pegol in Patients with Crohnʼs Disease Who Have Failed Previous TNF Inhibitor Therapies: 1149

The American journal of gastroenterology, 2010-10, Vol.105, p.S416

2010

Link zum Volltext

Verfügbarkeit prüfen

Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease

Journal of Crohn's and colitis, 2012-02, Vol.6 (1), p.21-28

2012

Link zum Volltext

Verfügbarkeit prüfen

Compassionate Use of Certolizumab Pegol in Patients with Crohnʼs Disease for Whom Treatment with One or Two Anti-TNFs Failed: 997

The American journal of gastroenterology, 2007-09, Vol.102, p.S484

2007

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Mit welcher CED-Therapie in die Schwangerschaft?

Tu1717 - Cedur: Implementation of a Long-Term Observation Registry in German IBD Patients

Iron Replacement Therapy for Secondary Thrombocytosis in Inflammatory Bowel Disease: Results of a Randomized Controlled Study – The ThromboVIT Trial

Corrigendum to: Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial

Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial

Su2091 Results of a Phase II, Randomized, Double Blind, Controlled Trial of the Efficacy of Active Therapeutic Immunization With TNF-Kinoid in Patients With Moderate to Severe Crohn's Disease With Secondary Resistance to TNFα Antagonist

Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program

Recombinant Erythropoietin for the Treatment of Anemia in Inflammatory Bowel Disease

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a Phase 3 study

867e: EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY

Letter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease

Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial

Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study

Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency

Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease

Compassionate Use of Certolizumab Pegol in Patients with Crohnʼs Disease Who Have Failed Previous TNF Inhibitor Therapies: 1149

Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease

Compassionate Use of Certolizumab Pegol in Patients with Crohnʼs Disease for Whom Treatment with One or Two Anti-TNFs Failed: 997

Suchergebnisse filtern